Wedbush Brokers Decrease Earnings Estimates for NBIX

Neurocrine Biosciences, Inc. (NASDAQ:NBIXFree Report) – Equities research analysts at Wedbush cut their FY2025 earnings per share (EPS) estimates for Neurocrine Biosciences in a note issued to investors on Tuesday, July 15th. Wedbush analyst L. Chico now anticipates that the company will earn $3.84 per share for the year, down from their previous estimate of $3.92. Wedbush currently has a “Outperform” rating on the stock. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $4.28 per share. Wedbush also issued estimates for Neurocrine Biosciences’ Q4 2025 earnings at $1.47 EPS.

Neurocrine Biosciences (NASDAQ:NBIXGet Free Report) last announced its earnings results on Monday, May 5th. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.70 by ($0.62). The firm had revenue of $572.60 million for the quarter, compared to analyst estimates of $587.06 million. Neurocrine Biosciences had a net margin of 12.68% and a return on equity of 11.81%. Neurocrine Biosciences’s revenue for the quarter was up 11.1% compared to the same quarter last year. During the same period last year, the firm earned $1.20 earnings per share.

A number of other analysts have also issued reports on NBIX. UBS Group increased their target price on Neurocrine Biosciences from $152.00 to $174.00 and gave the company a “buy” rating in a report on Wednesday, July 9th. Royal Bank Of Canada restated an “outperform” rating and issued a $145.00 target price on shares of Neurocrine Biosciences in a report on Monday, June 2nd. JPMorgan Chase & Co. increased their target price on Neurocrine Biosciences from $183.00 to $184.00 and gave the company an “overweight” rating in a report on Wednesday, March 26th. Needham & Company LLC increased their target price on Neurocrine Biosciences from $138.00 to $139.00 and gave the company a “buy” rating in a report on Tuesday, May 6th. Finally, Wall Street Zen lowered Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a report on Thursday, March 20th. Three research analysts have rated the stock with a hold rating and twenty-one have assigned a buy rating to the stock. Based on data from MarketBeat.com, Neurocrine Biosciences has an average rating of “Moderate Buy” and a consensus price target of $163.91.

Check Out Our Latest Stock Analysis on Neurocrine Biosciences

Neurocrine Biosciences Stock Up 1.7%

NBIX opened at $133.48 on Wednesday. The stock has a fifty day moving average of $125.18 and a 200-day moving average of $121.53. The firm has a market capitalization of $13.21 billion, a P/E ratio of 45.25, a PEG ratio of 1.35 and a beta of 0.24. Neurocrine Biosciences has a 12-month low of $84.23 and a 12-month high of $157.98.

Institutional Investors Weigh In On Neurocrine Biosciences

Several hedge funds and other institutional investors have recently made changes to their positions in NBIX. Geneos Wealth Management Inc. grew its position in shares of Neurocrine Biosciences by 143.6% in the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock valued at $25,000 after purchasing an additional 135 shares during the last quarter. Huntington National Bank grew its position in shares of Neurocrine Biosciences by 73.5% in the fourth quarter. Huntington National Bank now owns 229 shares of the company’s stock valued at $31,000 after purchasing an additional 97 shares during the last quarter. WPG Advisers LLC acquired a new stake in shares of Neurocrine Biosciences in the first quarter valued at about $32,000. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Neurocrine Biosciences in the first quarter valued at about $34,000. Finally, GeoWealth Management LLC grew its position in shares of Neurocrine Biosciences by 65.4% in the fourth quarter. GeoWealth Management LLC now owns 258 shares of the company’s stock valued at $35,000 after purchasing an additional 102 shares during the last quarter. 92.59% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Neurocrine Biosciences

In other Neurocrine Biosciences news, Director William H. Rastetter sold 30,000 shares of the stock in a transaction on Monday, May 5th. The shares were sold at an average price of $110.20, for a total transaction of $3,306,000.00. Following the transaction, the director directly owned 37,491 shares of the company’s stock, valued at $4,131,508.20. This represents a 44.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Ingrid Delaet sold 457 shares of the firm’s stock in a transaction dated Thursday, July 10th. The shares were sold at an average price of $135.00, for a total value of $61,695.00. Following the completion of the sale, the insider directly owned 4,730 shares in the company, valued at approximately $638,550. This represents a 8.81% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 120,251 shares of company stock valued at $14,978,602. Corporate insiders own 4.80% of the company’s stock.

Neurocrine Biosciences Company Profile

(Get Free Report)

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

See Also

Earnings History and Estimates for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.